Organon's Hormone-Free IUD Shows Strong 6-Year Efficacy in Phase 3 Study

  • Organon's MIUDELLA®, a hormone-free IUD, demonstrated a 6-year Pearl Index of 0.93 and a cumulative pregnancy rate of 3.9% in interim Phase 3 study results.
  • The study, conducted by Sebela Women’s Health, involved 465 participants for efficacy and 592 for safety through 6 years of use.
  • FDA review of the supplemental New Drug Application (sNDA) for extended use up to 6 years is expected in Q2 2027.
  • Common adverse events included heavy menstrual bleeding, dysmenorrhea, and pelvic discomfort, with 8.7% discontinuation rate in year 1 due to bleeding or pain.
  • Organon licensed global rights to MIUDELLA from Sebela Women’s Health in June 2026.

Organon's positive Phase 3 results for MIUDELLA reinforce the growing demand for hormone-free contraceptive options. The study's long-term efficacy data positions MIUDELLA as a potential leader in the intrauterine device market, especially as regulatory approval for extended use approaches. The healthcare sector continues to prioritize non-hormonal solutions, driven by patient preferences and evolving medical guidelines.

Regulatory Approval
Whether the FDA will approve the sNDA for extended use up to 6 years by Q2 2027, which could expand MIUDELLA's market potential.
Market Adoption
The pace at which healthcare providers and patients adopt MIUDELLA, given its hormone-free nature and long-term efficacy data.
Competitive Positioning
How Organon positions MIUDELLA against existing hormone-free IUDs and other contraceptive options in the women's health market.